stocks logo

PMN

ProMIS Neurosciences Inc
$
0.844
+0.004(0.476%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.890
Open
0.829
VWAP
0.86
Vol
933.96K
Mkt Cap
27.61M
Low
0.8181
Amount
798.57K
EV/EBITDA(TTM)
--
Total Shares
18.96M
EV
19.21M
EV/OCF(TTM)
--
P/S(TTM)
--
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
Show More
2 Analyst Rating
up Image
314.45% Upside
Wall Street analysts forecast PMN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PMN is 3.50 USD with a low forecast of 3.00 USD and a high forecast of 4.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
up Image
314.45% Upside
Current: 0.844
sliders
Low
3.00
Averages
3.50
High
4.00
H.C. Wainwright
Raghuram Selvaraju
initiated
$4
2025-07-14
Reason
H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of ProMIS Neurosciences with a Buy rating and $4 price target. ProMIS is an emerging biotechnology company focused on developing novel therapeutic and vaccine-based approaches to address serious unmet medical needs in neurology, the analyst tells investors in a research note.
Maxim
NULL -> Buy
initiated
$3
2025-05-12
Reason
Maxim initiated coverage of ProMIS Neurosciences with a Buy rating and $3 price target.
Guggenheim
Eddie Hickman
Strong Buy
Reiterates
$6
2025-04-01
Reason
Guggenheim
Eddie Hickman
Strong Buy
Reiterates
n/a
2025-02-26
Reason

Valuation Metrics

The current forward P/E ratio for ProMIS Neurosciences Inc (PMN.O) is -1.31, compared to its 5-year average forward P/E of -1.04. For a more detailed relative valuation and DCF analysis to assess ProMIS Neurosciences Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.04
Current PE
-1.31
Overvalued PE
0.63
Undervalued PE
-2.71

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.08
Current EV/EBITDA
-0.94
Overvalued EV/EBITDA
-0.02
Undervalued EV/EBITDA
-2.14

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2125.06
Current PS
0.00
Overvalued PS
6502.39
Undervalued PS
-2252.27

Financials

Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+102.90%
-7.46M
Operating Profit
FY2025Q1
YoY :
+102.14%
-7.35M
Net Income after Tax
FY2025Q1
YoY :
+10.53%
-0.21
EPS - Diluted
FY2025Q1
N/A
Free Cash Flow

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
14.6K
USD
Months
0-12
4
268.2K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

PMN News & Events

Events Timeline

2025-07-28 (ET)
2025-07-28
07:08:32
ProMIS Neurosciences announces private placement financing
select
2025-07-22 (ET)
2025-07-22
07:18:11
ProMIS Neurosciences announces private placement financing
select
2025-07-22
07:16:35
ProMIS Neurosciences announces $0.8M registered direct offering
select
Sign Up For More Events

News

9.5
07-23Benzinga
Why Vicor Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket
2.0
07-22TipRanks
3 Penny Stocks to Watch Now, 7/22/25
4.5
07-21TipRanks
Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
Sign Up For More News

FAQ

arrow icon

What is ProMIS Neurosciences Inc (PMN) stock price today?

The current price of PMN is 0.844499 USD — it has increased 0.48 % in the last trading day.

arrow icon

What is ProMIS Neurosciences Inc (PMN)'s business?

arrow icon

What is the price predicton of PMN Stock?

arrow icon

What is ProMIS Neurosciences Inc (PMN)'s revenue for the last quarter?

arrow icon

What is ProMIS Neurosciences Inc (PMN)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for ProMIS Neurosciences Inc (PMN)'s fundamentals?

arrow icon

How many employees does ProMIS Neurosciences Inc (PMN). have?

arrow icon

What is ProMIS Neurosciences Inc (PMN) market cap?